Skip to main content
OpenTrials
Completed

NCT Number: NCT05308745

Effects of Yakult Ingestion in Residents and Staffs at Indonesian Elderly Houses

A study to investigate the effect of Yakult® containing L. casei Shirota on the intestinal microbiota, intestinal environment, and stool frequency in healthy adult and elderly subjects in Indonesia. The clinical phase of this study was conducted for 26 weeks in three different elderly houses. The subjects were grouped into two categories: probiotic and placebo group, according whether the subjects consumed product or placebo samples. Fecal sampling were taken three times during the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–95 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wana Seraya Elderly House, Denpasar, Badung, Indonesia

Loading trial locations.

About this study

The study investigates the ingestion effect of a commercialized probiotic milk drink, Yakult®, for residents and staffs at Indonesian elderly houses (age limit: 18 - 95 years old). The study will be conducted as a double blind, placebo controlled parallel comparison study. There will be 26 weeks used for the study, comprised of: A 2-week baseline assessment period, and 24-week probiotic or placebo intake period.

From 112 subjects, the participants will be grouped into two: probiotic and placebo group. Those in probiotic group will consume Yakult® (Fermented milk drink containing over 6.5×10^9 CFUs of L. casei Shirota/65 ml), while placebo group will consume the placebo product (taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product). The treatment intake will be done for 24 weeks (182 days).

During the study, the participants are expected to fill questionnaire of frequency of bowel movements and Chinese Constipation Questionnaire to obtain the defecation frequency (Bristol Stool score) and abdominal symptom scores. Fecal samples will be collected three times: on the last day of the baseline period (day 14±1), 12 weeks (day 98±1) after intake period, after the 24-weeks intake period (day 182±1). Afterwards, the obtained fecal samples will be further analyzed for its microbial composition, level of short-chain fatty acids and putrefactive compounds.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Understand and sign written informed consent
  • Healthy adult and elderly subjects (adult: between 18 - 69 years old; elderly at least 70 years old.
  • No history of an adverse reaction to any of the components of the active or placebo versions of the probiotic product.
  • Can eat, regularly.
  • Has been diagnosed by doctors as healthy both physically and mentally.
  • Can abide by the experimental protocol.

Exclusion criteria

  • Excessive alcohol consumption (defined as follows: male; over 28 glasses a week, female; over 21 glasses/week).
  • Consume antibiotics or laxatives at least 2-week prior screening period.
  • Consume ingestion of fermented dairy foods (yogurt), probiotic foods and/or prebiotic at least 2 weeks prior to the study.
  • Reported current usage of Narcotics and Psychotropic,
  • History of GI surgery i.e. Colectomy and Enterectomy.
  • Symptoms meeting to Rome IV diagnostic criteria for irritable bowel syndrome
  • Pregnant or childbearing women

Treatment and study plan

Yakult®

Dietary Supplement

Fermented milk drink containing over 6.5×10^9 CFUs of L. casei Shirota/65 ml

Placebo

Dietary Supplement

Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product

Primary outcomes

  1. Beneficial impact of Yakult on intestinal microbiota and intestinal environment compared to Placebo

    Time frame: up to 23 months

    Fecal samples will be analyzed for its microbiota composition using YIF-SCAN (Yakult Intestinal Flora Scan) and 16S rRNA gene sequencing will be utilized to measure the intestinal microbiota. The basic principle of YIF-SCAN is the quantitative RT-PCR method. The microbiota composition that will be analyzed is the number and ratio of beneficial bacteria (ex. Bifidobacterium) and harmful bacteria (Enterobacteriaceae, Enterococcus, C. perfringens, C. difficile etc.)

Secondary outcomes

  1. Frequency of bowel movements

    Time frame: up to 23 months

    Using the Bristol Stool scale and stool frequency questionnaire, the frequency of bowel movements are measured as Bristol Stool score

  2. Abdominal symptom scores

    Time frame: up to 23 months

    Using the Chinese Constipation questionnaire, bowel function and rectal symptoms are documented

  3. The concentration of total short chain fatty acids

    Time frame: up to 23 months

    The level of several short-chain fatty acids are measured from stool samples. These fatty acids are acetic acid, propionic acid, butyric acid, iso-butyric acid, succinic acid, lactic acid, formic acid, iso-valeric acid, valeric acid

  4. The contents of putrefactive production

    Time frame: up to 23 months

    The concentration of several putrefactive compounds are measured from stool samples. These compounds include ammonia, phenol, indole, p-cresol.

Sponsors and collaborators

Lead sponsor

Endang Sutriswati Rahayu

Other

Collaborators

  • Yakult Honsha Co., LTD

Registry information

Official study title

The Effects of a Probiotic Milk Drink, Yakult®, Containing Lactobacillus Casei Shirota on the Intestinal Microbiota and Intestinal Environment in Residents and Staff at Elderly Houses in Indonesia

Important dates

Study start
2018
Primary completion
2018
Study completion
2022
First posted
Apr 4, 2022
Registry last updated
Apr 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.